Mark Rigby

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

Mark Rigby, Kristina M. Harris, Ashley Pinckney et al. · Journal of Clinical Investigation · 2015 · 286 citations · Full text

Ultrasound-guided central venous catheter placement decreases complications and decreases placement attempts compared with the landmark technique in patients in a pediatric intensive care unit*

Curt D. Froehlich, Mark Rigby, Eli S. Rosenberg et al. · Critical Care Medicine · 2009 · 247 citations

Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes

Teresa Quattrin, Michael J. Haller, Andrea K. Steck et al. · New England Journal of Medicine · 2020 · 239 citations

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

Mark Rigby, Linda A. DiMeglio, Marc Rendell et al. · The Lancet Diabetes & Endocrinology · 2013 · 201 citations · Full text

Memory T Cells, Autoimmune Disease, Diabetes +9

Heterogeneous expression of four MAP kinase isoforms in human tissues

Fernando A. González, David Raden, Mark Rigby et al. · FEBS Letters · 1992 · 145 citations